Elyse N. Tomaszewski

Learn More
The goal of the current study is to examine the biological effects of epithelial-specific tumor suppressor maspin on tumor host immune response. Accumulated evidence demonstrates an anti-tumor effect of maspin on tumor growth, invasion and metastasis. The molecular mechanism underlying these biological functions of maspin is thought to be through histone(More)
Myeloid-derived suppressor cells (MDSCs) are one of the major components of the immune-suppressive network, play key roles in tumor progression and limit therapeutic responses. Recently, we reported that tumor spheres formed by breast cancer cell lines were visibly smaller in a Th1 enriched microenvironment with significantly reduced differentiation of MDSC(More)
A phase I trial of infusing anti-CD3 × anti-CD20 bispecific antibody (CD20Bi) armed activated T cells (aATC) was conducted in high-risk/refractory non-Hodgkin's lymphoma patients to determine whether aATC infusions are safe, affect immune recovery, and induce an antilymphoma effect. Ex vivo expanded ATC from 12 patients were armed with anti-CD20 bispecific(More)
Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab during ex vivo T cell expansion could augment anti-CD3-driven T cell(More)
Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
e18570^ Background: Relapse continues to be a challenge affecting patient's survival in multiple myeloma. Chemoresistance of myeloma stem cell MMSC (CD138-CD20+) remains an obstacle to complete disease eradication. METHODS We utilized the presence of CD20 antigen on MMSC to target them with ex vivo expanded anti-CD3 activated autologous T cells armed with(More)
2548 Background: Nontoxic immunologic targeting strategies for the treatment of metastatic breast cancer (MBC) are needed. Anti-CD3 activated T cells (ATC) retargeted (armed) with anti-CD3 x anti-Her2 bispecific antibody HER2Bi) exhibit high levels of specific cytotoxicity, proliferate, and secrete cytokines/chemokines. This study was designed to test the(More)
This phase Ib clinical trial evaluated whether pretargeting of CD20(+) clonogenic myeloma precursor cells (CMPCs) with anti-CD3 × anti-CD20 bispecific antibody-armed T cells (BATs) before autologous stem cell transplantation (SCT) in patients with standard-risk and high-risk multiple myeloma would induce antimyeloma immunity that could be detected and(More)
  • 1